E-Cigarettes: A Disruptive Technology That Revolutionizes Our Field? by Fagerstrom, Karl et al.
Nicotine & Tobacco Research, 2015, 125–126
doi:10.1093/ntr/ntu240
Editorial
© The Author 2015. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. 
For permissions, please e-mail: journals.permissions@oup.com.
125
E-Cigarettes: A Disruptive Technology That Revolutionizes Our Field?
Karl Fagerstrom PhD1, Jean-Francois Etter PhD2,  
Jennifer B. Unger PhD3
1Fagerstrom Consulting, Sweden; 2Institute of Global Health, 
University of Geneva, Switzerland; 3Department of Preventive 
Medicine, University of Southern California, Los Angeles, CA
Corresponding Author: Karl Fagerstrom, PhD, Framnäsvägen 8, 
Vaxholm 18531, Sweden. E-mail: kark.fagerstrom@swipnet.se
Electronic cigarettes (EC) or electronic nicotine delivery systems 
(ENDS) were invented by the Chinese pharmacist Lik Hon and were 
initially developed by the Chinese company Ruyan. Early models 
looked very much like cigarettes, and therefore EC was a relatively 
appropriate name. However, they are now available in numerous 
shapes and sizes with different components (“mods”) that can be 
assembled by users (“vapers”); therefore ENDS may be a more accu-
rate name for these devices. They were first marketed in Europe and 
the United States in 2006. Sales of ENDS were initially modest, pos-
sibly because the technology was unreliable and the nicotine delivery 
was very limited.1 ENDS were first met by curiosity and an open 
mind by most researchers and tobacco policy advocates. After some 
years with modest growth on the market but with radical techno-
logical development and a big growth in tobacco company interest, 
sales of ENDS increased dramatically around 2010 and have now 
surpassed sales of nicotine replacement therapy (NRT) despite its 
35 years on the market. Some financial analysts project that ENDS 
will overtake the sales of traditional cigarettes within 10  years.2 
Among adults in the United States, awareness of ENDS increased 
from 41% in 2010 to 80% in 2013. Ever use increased from 10% to 
37% among smokers and from 3% to 10% among former smokers.3
With the steep increase in market penetration and an absence of 
interest in ENDS from the pharmaceutical industry, the tobacco indus-
try has decisively moved into the ENDS business. Today almost all of 
the big international tobacco companies have their own ENDS prod-
ucts. That may explain the change in attitude among tobacco policy 
advocates from an initial open mind to a much more negative outlook. 
Few clinicians and researchers want to be engaged in research that can 
benefit the tobacco industry. Many anti-tobacco policy makers believe 
that ENDS will not benefit public health at the population level, even 
if they may provide a harm reduction mechanism for certain cigarette 
smokers who are unwilling or unable to quit. The discussion around 
ENDS has become very polarized with two very different letters of 
advice being sent to Margaret Chan, the Director General of WHO by 
different groups of researchers, with very different perspectives on the 
value and potential dangers of ENDS.
ENDS present new regulatory challenges to governments. They 
have been banned in several countries such as Australia, New Zealand, 
Canada, and Sweden. Regulatory agencies in other countries are strug-
gling with how to regulate them. In the United States, the Center 
for Tobacco Products at the FDA has started a process to regulate 
ENDS by deeming the FDA’s jurisdiction over them, but the process 
of implementing specific regulations is likely to be slow and politically 
fraught. In the EU, ENDS are permitted and have been given two roads 
in its Tobacco Products Directive of 2014.4 They can be regulated as 
either a medicine like NRT, or as a general consumer product. In the 
medicine route, they can be advertised with efficacy claims and there 
are no limitations on nicotine content in the cartridges. The consumer 
goods route will not allow efficacy claims, advertising and unlimited 
nicotine content.
The polarized views are to an extent a consequence of the limited 
research that has been conducted on the short-term and long-term 
health effects of ENDS. ENDS are a relatively new product in the 
marketplace and their design is still evolving. Thus, there has not 
been sufficient time for the long-term health effects of ENDS to be 
determined with any certainty. Studies are just beginning to address 
questions such as whether ENDS help cigarette smokers quit and 
whether ENDS recruit young people into nicotine dependence. Many 
opinions have been formed in the absence of sound evidence. For this 
reason, N&TR has decided to devote a whole issue to research on 
ENDS to help further understand them and their role in the tobacco/
nicotine landscape. This special issue includes a wide variety of 
papers from chemical composition of ENDS liquids to performance 
to user characteristics. The papers provide many new insights. In 
particular concerns have been voiced about unnecessary toxicants in 
ENDS often resulting from heated flavorings. Many sweet-flavored 
ENDS contain diacetyl and propionyl, chemicals that are approved 
for food use, but can have adverse effects on the respiratory system. 
The concentrations obtained were however 10–100 times lower than 
seen in cigarettes.5 Nicotine poisoning also might result from inges-
tion or skin contact with ENDS liquids. A poison centre in Texas 
reported an increase in the number of reports for ENDS, mostly 
due to ingestion (78%). The most frequent effects were vomiting 
(20%), nausea (10%), and headache (4%). Most of the exposures 
occurred in young children.6 The extent to which nicotine and other 
substances can be absorbed by non-vapers remains to be studied.7 
The accuracy of labeling is not always very good but improving. One 
study reported that the nicotine content of two-thirds of samples 
assessed were more than 10% outside stated levels.8
Efforts to quantify the health effects of ENDS are complicated 
by the difficulty of measuring the doses of nicotine and other chemi-
cals inhaled by the user. Nicotine yield in vapor can vary as much as 
50 times due to puff topography, liquid strength and composition, 
and design features of ENDS, such as capacity to raise temperature.9 
Newer ENDS can be controlled either by a button or by an air-
flow sensor. The airflow rates required to produce aerosol and the 
aerosol adsorbances were lower for button-activated models than 
for airflow-activated models. Pressure drop was also lower across 
button activated products which causes users to drag harder on 
air-flow activated systems.10 Among experienced users using their 
preferred product it was found that 10 puffs at 16 ng/ml could give 
an increase in plasma nicotine concentrations similar to tobacco 
cigarettes.11 Some pulmonary absorption of nicotine seems to take 
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place since peak nicotine levels were achieved within 5 min of start-
ing ENDS use. The study also found that the amount of nicotine 
obtained by users increases over time as users become more experi-
enced.12 There are many ways to determine the nicotine delivery of 
ENDS. In order to arrive at a standard by which different products 
can be compared, it has been suggested that the total dose and its 
rate should be measured, for example, as the nicotine per puff or 
per second by a given ENDS design under a given use condition.13 
Using the nicotine flux as a parameter for characterizing ENDS was 
questioned in a letter to the editor. It was questioned on the grounds 
that it could drive down the nicotine delivery and make ENDS less 
effective while it would provide no benefit in terms of safety.14
ENDS, when compared with smokeless tobacco, are being 
quickly embraced by cigarette smokers, either as a replacement for 
cigarettes or in addition to cigarettes.15 It is not yet clear whether 
nicotine dependence will decrease, increase, or remain constant 
among cigarette smokers who switch to ENDS. ENDS users report 
being less dependent than they retrospectively reported having been 
on cigarettes prior to switching. However longer use, button oper-
ated systems and higher nicotine containing cartridges were asso-
ciated with higher dependence.16 American adult smokers reported 
that ENDS had greater appeal than smokeless tobacco. When ask-
ing vapers about expectancies, ENDS were more positively rated 
than cigarettes on health risks, reduction of craving and withdrawal 
symptoms, sense of taste and negative social impression, but had 
less positive expectancies for weight control, stimulation and reduc-
tion of stress and negative effect. ENDS were rated as superior to 
NRT for taste, satisfaction, health risks, negative physical feelings, 
cost and reduction of craving, negative effect and stress.17 In a two-
year longitudinal study of metropolitan US  adult smokers, inten-
sive ENDS users were six times as likely as non-users or triers to 
report quitting smoking cigarettes18 and longer duration of use has 
been found to be associated with fewer cigarettes smoked.19 Among 
hospitalized smokers ENDS use was more common among heavier, 
younger, and higher educated smokers.20 Between 2011 and 2013, 
the number of never-smoking youth who had tried ENDS increased 
three-fold, and intention to smoke cigarettes has been reported to be 
greater among those who had tried ENDS compared with those who 
had not tried ENDS.21 Another study found that 8% of non-smoking 
young adults had tried ENDS and 14% of this group of reported 
that they were current users.22
A National Institutes of Health–sponsored workshop identified 
research priorities that included standards to measure the contents and 
emissions of ENDS, biomarkers of exposure, physiological effects on 
tissues and organs, and potential as both a cessation aid and a gateway 
product to cigarette smoking.23 With this issue the guest editors hope 
that N&TR has contributed to a better informed discussion of ENDS.
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